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Abstract  1 
Therapeutic antibodies targeting disease associated antigens are key tools in the treatment of 2 
cancer and autoimmunity.  So far, therapeutic antibodies have targeted antigens which are, or 3 
are presumed to be, extracellular. A largely overlooked property of antibodies is their 4 
functional activity inside cells. The diverse literature dealing with intracellular antibodies 5 
emerged historically from studying the properties of some autoantibodies. The identification of 6 
TRIM21 as an intracellular Fc receptor, which links cytosolic antibody recognition to the 7 
ubiquitin proteasome system, brings this research into sharper focus. We review critically the 8 
research related to intracellular antibodies, link this to the TRIM21 effector mechanism and 9 
highlight how this work is exposing the previously restricted intracellular space to the potential 10 
of therapeutic antibodies.   11 
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Autoantibodies: friend or foe? 1 
Antibodies targeting self-cellular components, autoantibodies, are a defining feature 2 
particularly of the autoimmune rheumatic conditions systemic lupus erythematosus (SLE) and 3 
Sjögren’s syndrome (SS). Tissue specific autoimmune diseases, exemplified by multiple sclerosis 4 
(MS) and type I diabetes (T1D), also present with prominent and disease specific autoantibody 5 
profiles to self-antigens, many of which are intracellular. Autoantibodies have been studied 6 
extensively as a route to understanding the selective breakdown of self-tolerance which this 7 
phenomenon clearly illuminates. Generally considered to be a secondary manifestation of 8 
underlying regulatory defects in antigen presentation, perhaps linked to a dysregulated 9 
immune response to apoptotic and/or necrotic cell death, autoantibodies historically were 10 
considered to be contributors rather than primary mediators in disease initiation. However, 11 
some autoantibodies have been linked definitively with pathology, for instance in myasthenia 12 
gravis and Graves’ disease.  13 
In contrast to the perceived limited functional role of autoantibodies, they may in fact 14 
be revealing unrecognised capabilities of humoral immunity. The properties of disease-15 
ameliorating anti-IFNα autoantibodies detected in AIRE-deficient patients is consistent with this 16 
more nuanced assessment [1]. Natural antibodies, where antigen binding CDR3 regions are 17 
germ-line encoded un-mutated V(D)J gene segments, are often directed to self-antigens and 18 
are prevalent in healthy individuals [2]. Autoantibodies are associated with many diseases, 19 
including cancer and Alzheimer’s disease [3]. Their presence in serum often predates overt 20 
symptoms by many years, adding the need for vigilance to their long standing use in disease 21 
definition/classification [4-6]. The reduced rates of some cancers observed in autoimmune 22 
disease patients has led to speculation of possible beneficial effects of autoantibodies with 23 
precise specificity [7].  24 
 25 
 Identification of cell penetrating autoantibodies 26 
The idea that autoantibodies binding nuclear antigen (ANA), notably DNA or the so-27 
called ribonucleoprotein particles, could penetrate inside cells, enter the cell cytoplasm and 28 
modulate function, was first reported by Alarcon-Segovia et al in a series of papers beginning in 29 
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the 1970s [8-10]. Variable effects on cell viability by cell penetrating autoantibodies were 1 
claimed subsequently by a number of laboratories, using different in vivo cell culture systems 2 
[11-13]. Cell penetration was a property of some mouse and human monoclonal autoantibodies 3 
and was not isotype restricted [14]. Uptake of IgG autoantibodies into various cell types, 4 
including mononuclear cells, lymphocytes, hepatocytes, epithelial cells and neurons [10, 12, 15, 5 
16] was proposed initially to be via Fc gamma receptor mediated endocytosis [17]. Other 6 
mechanisms of uptake have been described [18-20]. However, it is clear that in much of these 7 
early data, there is insufficient resolution to determine whether antibodies are located in the 8 
cytosol and therefore whether antibodies have actually traversed the cell membrane.  9 
Because of the generally variable and confusing reports and notwithstanding the 10 
possibility of cell culture or fixation artefacts, much of this work was overlooked [21]. An 11 
intracellular function for antibodies was also counter to the prevailing view of humoral 12 
immunity focusing exclusively on extracellular antigens. Critically, being able to distinguish 13 
between true intracellular localisation for antibody in the cytosol and merely 14 
compartmentalisation within endosomes/lysosomes turned out to be difficult to achieve 15 
experimentally [22]. The action of conventional Fc receptors, particularly FcRn for example, 16 
could account for localisation and retention within the endolysosomal compartment. Antibody 17 
engagement by other signalling Fc receptors, expressed on a variety of lymphoid and myeloid 18 
cells (but not generally by epithelial or endothelial cells) could account for additional functional 19 
consequences in some experiments. Instead, it was considered that cell penetration by 20 
autoantibodies was likely to be a rare or aberrant phenomenon, which nevertheless could have 21 
important consequences for autoimmune disease, by influencing tolerance to intracellular self-22 
antigen and by initiating apoptotic cell death [9, 11, 23]. Cell penetration has also been 23 
proposed as an intrinsic property of some germ-line encoded natural autoantibodies, which, if 24 
correct, has led to speculation of additional immunological functions for these molecules [2, 24, 25 
25]. Importantly, it was also recognised that delivery of antibodies into the cell could open up 26 
new therapeutic areas [23]. 27 
  28 
 29 
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Characteristics of intracellular and cell penetrating antibodies 1 
Several strands of research address the functional capabilities of antibodies inside cells 2 
and the properties which contribute to stability and cell penetration. Much of this effort has 3 
been driven by their therapeutic potential.  4 
Intrabodies are antibody fragments composed of linked variable region heavy and light 5 
chains used to target intracellular proteins [26]. Targeting of disease specific protein variants 6 
using intrabodies for therapeutic purposes has been effective in cell culture [27-29]. Screening 7 
of recombinant antibody libraries for optimisation of intrabody structure with enhanced 8 
binding characteristics has been used [30-32]. The reducing environment inside cells negatively 9 
impacting disulphide bridge formation, as well as improper glycosylation, have been seen as a 10 
key factors affecting IgG structure and function in the cytosol [33]. Introduction of intrabodies 11 
usually requires expression of DNA plasmids encoding antibody sequences within the target 12 
cell, either by transfection or by gene therapy approaches using adeno-associated virus in the 13 
whole animal [34]. Chemical modification to aid delivery or covalent fusion of antibody 14 
molecules with cell-penetrating peptides, such as HIV-1 TAT, have also been used, as well as 15 
modification with amino acid motifs which support localisation to distinct subcellular 16 
compartments, for example endoplasmic reticulum retention using the KDEL motif [35-37]. The 17 
efficiency of some of these mechanisms of introduction has been questioned [22]. Therefore, 18 
while intrabodies demonstrate the effectiveness of antibodies inside cells and offer a means for 19 
optimisation of stability and binding characteristics, the technology is at present limited by the 20 
difficulties of first delivering them into the cytosol.     21 
Cell-penetrating autoantibodies have been identified, with many of the reports focusing 22 
particularly on the properties of anti-DNA monoclonal autoantibodies. Sequencing studies of VH 23 
regions of cell-penetrating anti-DNA autoantibodies showed a preference for charged amino 24 
acids in the antigen binding (CDR3) region [38, 39]. Defined motifs were not identified, 25 
admittedly from comparison of a relatively small number of anti-DNA monoclonal antibodies 26 
(n=6), although it was proposed that the position of a number of arginine residues could 27 
resemble nuclear localisation signals and thereby influence trafficking [40]. A single human IgG 28 
monoclonal anti-DNA autoantibody, clone 3E10, has been studied in detail [39, 41-43]. 29 
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Antibody Fab and single chain Fv fragments (scFv), a construct similar to intrabodies composed 1 
of only the variable heavy and light, VH and VL, segments from clone 3E10, efficiently 2 
penetrated into cells and in addition localised to the nucleus. Localization therefore was a 3 
property of the antigen binding region of 3E10 and independent of Fc receptors [38, 44]. 4 
Mutations which enhanced the ability of 3E10 scFv fragments to penetrate cell nuclei and 5 
precipitate DNA damage have been identified and 3E10 appeared to be particularly toxic to 6 
cancer cells with dysregulated DNA repair pathways, for instance with BRCA2 mutations [45, 7 
46]. Cellular uptake into tumour cells of 3E10 scFv was enhanced by the presence of 8 
extracellular DNA [39], although 3E10 also selectively immunoprecipitated heavy chain of 9 
myosin IIb on the cell surface of muscle cells, implying both a role for this protein in cell uptake 10 
but also a degree of cross- or poly- reactivity for the antibody [47]. Purified 3E10 IgG has been 11 
investigated as a potential therapeutic agent in its own right and as a delivery vehicle for 12 
covalently attached moieties [48]. Bivalent or bispecific antibody derivatives which take 13 
advantage of the cell-penetrating properties of 3E10, but which target, in addition, disease 14 
associated protein variants, have been shown to be effective [49, 50]. A large literature 15 
therefore reports the investigation of cell penetration and intracellular localisation, particularly 16 
of anti-DNA autoantibodies. However, the requirements for cell penetration have not been 17 
formally defined and the caveats we have outlined of proving true cytosolic delivery in most 18 
cases remain. Also, it is not clear whether the characteristics of these antibodies are rare or 19 
unique and therefore not representative of normal antibody function. 20 
  A murine anti-DNA autoantibody with unique characteristics, clone 3D8, has been used 21 
to develop whole IgG antibodies reportedly capable of cell penetration, called cytotransmabs 22 
[51]. In common with clone 3E10, 3D8 scFv internalized into living cells, but was capable of 23 
hydrolyzing DNA and RNA and of localization to the cell cytoplasm [52]. Cell penetration by 3D8 24 
was reportedly mediated by the single VL segment [53]. The 3D8 VL segment was used as a 25 
targeting adaptor by engineering it into the human therapeutic antibodies adalimumab 26 
(Humira®) and bevacizumab (Avastin®). The resulting humanized recombinant chimaeric 27 
antibodies were efficiently internalized into the cytoplasm in live cells, while maintaining 28 
binding affinity for their target antigen, tumour necrosis factor alpha (TNF-α) and vascular 29 
7 
 
endothelial growth factor A (VEGF-A), respectively [51]. Cytotransmabs were reported to be 1 
internalized by endocytosis through interactions with cell surface heparin sulfate proteoglycan 2 
and to escape from early endosomes into the cytosol where they were stable for more than 6 h. 3 
Degradation of internalized cytotransmabs was inhibited by drug MG132, indicating the 4 
involvement of proteasomes in their turnover [51]. Again, however, the data presented in these 5 
reports do not provide sufficient resolution to prove definitively cytosolic antibody delivery and 6 
the underlying molecular mechanism by which cytotransmabs escape from early endosomes 7 
into the cytosol is not addressed.  8 
In vitro screening systems have been developed to optimize cytotransmabs for stability 9 
and cell-penetration, as well as to identify the cellular factors involved. A method that enables 10 
direct assay of the efficiency of antibody penetration into HeLa cells based on split GFP 11 
complementation has been developed for these purposes [54]. Such systems show cytosolic 12 
antibody delivery, but at low frequency [22, 51]. A cell-free protein synthesis system was also 13 
developed in order to screen large numbers of antibodies for enhanced cytosol-penetrating 14 
characteristics [55]. Clearly, if the claims presented in these reports can be verified, then this 15 
technology will have important practical applicability for therapeutic antibody production, by 16 
the direct targeting of disease associated protein variants in the cytosol [51, 55].  17 
 18 
TRIM21 is a cytosolic Fc receptor required for antibody-dependent pathogen restriction 19 
During infection, antibodies are delivered efficiently to the cytosol when bound to 20 
obligate intracellular pathogens, such as viruses and bacteria [56, 57]. Once in the cytosol, 21 
antibodies contribute to innate immune signalling through NFkB and IRF3 pathway activation. 22 
They also neutralise pathogens via proteasome-dependent degradation. These sensor and 23 
effector functions are dependent on recruitment of the cytosolic antibody receptor TRIM21 24 
[58]. The terms antibody dependent intracellular neutralisation (ADIN) and intracellular 25 
antibody-mediated degradation (IAMD) have been coined in order to describe the TRIM21 26 
antibody effector mechanism [59].   27 
TRIM21 is a member of the tripartite motif (TRIM) protein family of RING E3 ubiquitin 28 
ligases. TRIM21 was first identified as an antibody binding protein of unusual structure by yeast 29 
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two-hybrid analysis and by investigation of its auto-antigenic characteristics compared to other 1 
related TRIM proteins [60, 61]. The TRIM21 interaction with immunoglobulins was found to 2 
occur with specificity and extremely high affinity, requiring a complex tertiary fold of the 3 
carboxyl-terminal B30.2 domain of TRIM21, binding to residues on Fc from both CH2 and CH3 [62, 4 
63]. The TRIM21/Fc interaction exemplifies a general mechanism of B30.2 domain binding to 5 
complex conformational epitopes inside cells. Other examples identified so far, are retroviral 6 
restriction factor TRIM5 targeting the HIV capsid and the  T cell receptor BTN3A1 binding of 7 
bacterial phosphoantigen [64-66]. These molecules link specific recognition of unusual 8 
intracellular antigenic epitopes to potent effector functions. 9 
 The precise molecular mechanisms involved in antibody bound pathogen restriction by 10 
TRIM21 are complex and involve a number of essential cofactors [67]. The first step in TRIM21 11 
activation is recruitment of the E2 enzyme Ube2W and catalysis of auto-mono-ubiquitination 12 
[68]. The E2 heterodimer Ube2N/2V2 is then recruited, which uses the mono-ubiquitination to 13 
prime anchored lysine-63 poly-ubiquitin chain extension. Ubiquitinated TRIM21, like TRIM5, is a 14 
substrate for the proteasome and both proteins depend on proteasomes to degrade targeted 15 
viral complexes. Lysine-63 poly-ubiquitin chains are subsequently liberated, a critical step linked 16 
to proteasome recruitment, which simultaneously contributes to the initiation of innate 17 
immune signalling [68]. TRIM21-mediated degradation of virus also requires the unfoldase and 18 
segregase enzyme p97/VCP [69].  19 
TRIM21 exhibits broad antibody class specificity, binding with high affinity to IgG, IgM 20 
and IgA, a characteristic unique to this Fc receptor [70]. By targeting structural elements of non-21 
enveloped viruses for degradation, TRIM21 allows for recognition of viral nucleic acid by host 22 
cytosolic DNA sensors such as cGAS and the RNA sensor RIG-I, to contribute to the triggering of 23 
innate immune signalling [71]. Biophysical characteristics of an anti-adenovirus capsid 24 
monoclonal antibody, 9c12, has allowed the kinetic and thermodynamic requirements for 25 
efficient TRIM21 recruitment and effector function to be determined [72]. The physiological 26 
relevance of these processes has been demonstrated using TRIM21 -/- knockout mice, which 27 
are more susceptible to lethal adenovirus infection [73].  28 
 29 
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TRIM21 and regulation of autophagy 1 
The elegant molecular and structural studies of TRIM21 function show, that upon 2 
infection, TRIM21 links immunoglobulin dependent recognition of virus in the cytosol to innate 3 
immune signalling and virus degradation contingent on proteasomes. In a separate line of 4 
research, a number of TRIM molecules, including TRIM21, have been linked to autophagy, a 5 
system for controlled degradation of cell components and of invading microorganisms, distinct 6 
from proteasome function [74]. TRIM21 has been shown to interact with ULK1, ATG16L1 and 7 
BECLIN1 (BECN1), key components for autophagosome assembly, and target cytosolic IRF3 for 8 
degradation by a process termed precision autophagy [75, 76]. So far, no mechanistic link to 9 
autophagy has been made for cytosolic immunoglobulins, although IRF3 is shown to bind to the 10 
TRIM21 B30.2 domain. It will be important to resolve these two functions for TRIM21 and to 11 
assess whether cytosolic immunoglobulin can influence cellular degradation mechanisms 12 
through these two mutually exclusive systems [75]. 13 
  14 
Therapeutic implications of intracellular antibodies  15 
There are obvious intracellular protein variants, associated particularly with cancer and 16 
with neurodegenerative disease, that make attractive therapeutic targets for antibodies [33, 17 
77, 78]. A bispecific scFv antibody linking the cell-penetrating anti-DNA antibody 3E10 to target 18 
MDM2 protein in the nucleus has been produced [50] and intrabodies expressed in cells have 19 
been used to disrupt the function of p53, p21Ras and BCR-ABL oncoproteins [30, 32, 35]. 20 
Cytotransmab functionality has been engineered into the commonly used human therapeutic 21 
antibodies adalimumab (Humira®) and bevacizumab (Avastin®), targeting TNF-α and VEGF-A, a 22 
strategy which offers the potential to block these proteins before their extracellular release 23 
[51].  Intracellular antibodies optimised for binding to the microtubule-associated protein TAU, 24 
found in neurofibrillary lesions of the brains of Alzheimer's disease sufferers have been 25 
investigated [79]. Recent data show that incoming TAU seeds are subject to degradation by 26 
antibody dependent recruitment of TRIM21, preventing them from triggering aggregation of 27 
soluble TAU protein [80].  28 
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These various reports show the potential for intracellular antibodies to disrupt function 1 
inside cells and could be used to identify and optimise relevant cellular machinery. Importantly, 2 
some reports now show therapeutic effectiveness in the whole animal. Antibodies to 3 
intracellular proteins delivered systemically have been shown to target intracellular antigen and 4 
prevent tumour growth in an in vivo system [81]. Three different immunogenic targets were 5 
used to assess the effectiveness of systemic antibody delivery. The three intracellular proteins 6 
used in the tumour vaccine studies were cancer-associated protein tyrosine phosphatase of 7 
regenerating liver 3 (PRL3), the polyomavirus middle T oncoprotein (mT) and the general 8 
reporter green fluorescent protein (EGFP). Tumour cells expressing these intracellular proteins, 9 
either endogenously or by over-expression, were inhibited by their respective exogenous 10 
antibodies [81]. Remarkably, tumour growth was also inhibited by host antibodies induced by 11 
vaccination with the appropriate antigen [81].  12 
Further evidence of specificity in this therapeutic approach has been presented. Two 13 
mouse melanoma cell lines with different PRL3 expression levels, B16F0 and B16F10, were used 14 
to induce tumours in mice. Tumour metastasis was inhibited by a humanized recombinant anti-15 
PRL3 antibody, with the level of inhibition correlating with PRL3 protein expression in the two 16 
cell lines [82]. Inhibitory effects of anti-PRL3 antibody on tumour metastasis induced by human 17 
cell lines with high endogenous PRL3 expression, including colorectal cancer cell line HCT116 18 
and ovarian cancer A2780, was also shown [82]. Inhibitory effects of the antibody were not 19 
seen using lung cancer line NCI-H460 which does not express PRL3, consistent with the notion 20 
that the efficiency of PRL3 antibody treatment correlated with PRL3 protein expression in the 21 
tumour. Similar experiments were used to show the potency of specific antibodies directed to 22 
other members of the PRL family of proteins, with PRL1 antibody specifically blocking 23 
metastatic tumour formation by PRL1, but not PRL3, expressing cells, and vice versa [83].  24 
 25 
Concluding Remarks and Future Perspectives 26 
During infection antibodies access the cytosol when bound to viral or bacterial 27 
pathogens. In the absence of infection, cells are either intrinsically or transiently permissive for 28 
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antibody penetration, or alternatively, cell penetration is a property of (presumably) a minor 1 
fraction of antibodies.  2 
The identification of intracellular TRIM21-dependent antibody recognition necessitates 3 
a re-assessment of the literature regarding the function of antibodies inside cells. It is possible 4 
that the potent effects of these antibodies have been overlooked because only a few antibody 5 
molecules are required to elicit TRIM21 effector function and cell penetration by antibody is 6 
normally infrequent [72]. Historically, there has been speculation of a mechanism of 7 
intracellular pathogen restriction by antibodies [84]. For example, anti-Sendai virus IgA 8 
monoclonal antibody neutralized Sendai virus in the cytoplasm [85]he identification of the 9 
TRIM21 mechanism provides a molecular explanation for some of these observations. The 10 
confusing and often contradictory effects of intracellular antibodies on cell function and 11 
viability, particularly the work on autoantibodies, could be interpreted as variation in efficiency 12 
of TRIM21 recruitment. Different antibody molecules, antibody derivatives and cells have been 13 
used. Effects of antibody isotype and allotype on TRIM21 binding were detected using defined 14 
variants of humanized recombinant IgG CAMPATH-1H (anti-CD52) in initial experiments [61]. It 15 
is likely that polymorphisms within TRIM21 will also affect its function.  16 
Theoretically, all antibodies capable of penetrating into the cell cytoplasm will engage 17 
TRIM21 and target intracellular antigens for degradation. However, the antibody effector 18 
mechanism is not fully understood and it is not yet clear what structural requirements allow for 19 
TRIM21 activation. Although TRIM21 appears to be expressed ubiquitously in cells and tissues, 20 
immune signalling will be induced dependent only on the availability of accessory factors, which 21 
may not be present [58, 68]. The role of TRIM21 in selective autophagy of activated IRF3, acting 22 
as a negative regulator of innate immune signalling, also requires further investigation in terms 23 
of antibody binding [75, 76]. 24 
TRIM21 (Ro52) is a prominent autoantigen in systemic lupus erythematosus, suggesting 25 
a link between autoantibody production and TRIM21 restriction. TRIM21 autoantibodies (anti-26 
Ro52) could be an attempt by humoral immunity to enhance TRIM21 function, perhaps 27 
precipitated by cryptic viral infection for which the TRIM21 mechanism has presumably evolved 28 
to combat. It is notable that TRIM21 binds Fc in a region at the CH2-CH3 interface that overlaps a 29 
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number of bacterial and virus encoded Fc receptors [86]. Convergent binding by molecules 1 
which are structurally distinct could imply pathogen interference with TRIM21 recruitment. The 2 
same argument goes for all autoantibodies which target intracellular components, suggesting 3 
more specific roles in autoimmune pathology than previously thought. The notion that some 4 
natural antibodies could be engaging TRIM21 suggests additional potential in pathogen 5 
restriction and immune regulation for the antigen inexperienced humoral immune response 6 
[87].    7 
Reports of the targeting of tumours with antibodies to intracellular antigens also 8 
necessitates a re-appraisal of intracellular oncoproteins as targets for anticancer therapy, 9 
although a number of questions remain [81]. The effects documented did not appear to be 10 
restricted by the antigen, as different molecules were targeted, even the cell marker EGFP 11 
which is not functionally related to tumorigenesis. It is unclear what properties of the 12 
antibodies allowed for intracellular delivery in these experiments, nor which effector 13 
mechanisms are involved. There are reports of broader protective effects of naturally occurring 14 
autoantibodies in disease, for example in HER2/neu positive breast cancer [88] and the 15 
possibility exists that diseased cells become transiently permissive for antibody uptake. If they 16 
can be verified, the data suggest that focusing on extracellular molecules for therapeutic 17 
antibodies, is over-restrictive. It will also be important to discover whether the TRIM21 effector 18 
mechanism is involved and if so whether it can be optimized for therapeutic benefit. Finally, 19 
these new data may help us to understand why the prevalence of certain cancers, notably 20 
breast, ovarian and endometrial, is reduced in patients with SLE [89, 90]. 21 
 22 
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Figure 1 IgG structure 3 
Diagram of antibody IgG structure highlighting antibody fragments and the site of TRIM21 4 
binding. TRIM21 binds via its carboxyl terminal B30.2 (also termed PRYSPRY) domain to the Fc 5 
portion of IgG at residues overlapping the CH2 and CH3 domains. TRIM21 is believed to form a 6 
head-to-tail dimer which binds both immunoglobulin G heavy chains simultaneously. 7 
Presence/absence of N-linked glycosylation did not affect TRIM21 interaction [61]. 8 
 9 
Figure 2 Intracellular antibodies recruit TRIM21  10 
Schematic representation of the possible effects of intracellular antibodies and TRIM21 11 
recruitment. Antibodies are delivered efficiently to the cytoplasm when bound to infectious 12 
micro-organisms. Inside cells, antibodies recruit the cytosolic Fc receptor TRIM21. A potent 13 
restriction mechanism is activated, resulting in proteasome dependent degradation of the 14 
antigenic target. Innate immune signalling via transcription factors NFkB and IRF3, induced in 15 
part, by free lysine-63 linked polyubiquitin chains (modified from [67]). In addition to 16 
proteasome activation and innate signalling, TRIM21 has been linked to the initiation of 17 
autophagy, resulting in the compartmentalisation and degradation of activated IRF3, thereby 18 
limiting immune signalling (modified from [76].  So far, cytosolic immunoglobulins have not 19 
been linked to TRIM21 dependent autophagy. Some antibodies, particularly autoantibodies, 20 
penetrate into the cell cytoplasm in the absence of infection. It is not known by what 21 
mechanism this is achieved nor whether cell penetrating (auto)-antibodies recruit TRIM21 and 22 
activate similar molecular programs.  23 
 24 
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Trends 3 
Monoclonal antibodies targeting extracellular antigens are well established as key therapeutic 4 
tools in cancer and autoimmunity. Prominent examples include anti-HER2/neu (Herceptin®) in 5 
the treatment of breast cancer, anti-TNFα (Humira®) used in rheumatoid and psoriatic arthritis 6 
and anti-VEGF-A (Avastin®) used for various types of cancer and (off-label) in age-related 7 
macular degeneration (wet-AMD).  8 
The majority of disease associated protein variants are arguably found inside cells. The function 9 
of antibodies inside cells is being investigated in order to target intracellular components for 10 
therapeutic benefit. 11 
To be therapeutically effective, the mechanism(s) by which antibodies cross the cell membrane 12 
and penetrate the cell cytoplasm need to be identified and optimized. Some autoantibodies 13 
which target intracellular components can penetrate inside cells and are being optimised for 14 
efficient intracellular delivery.   15 
Antibodies are carried efficiently inside the cell when bound to infectious micro-organisms, 16 
where they recruit the cytosolic Fc receptor TRIM21.  17 
TRIM21 links Fc mediated antibody recognition to the ubiquitin proteasome system, a general 18 
mechanism of immune-surveillance coupled to innate immune signaling and antigen 19 
degradation. TRIM21 has also been linked to initiation of autophagy. 20 
Antibodies to some intracellular proteins delivered systemically in vivo are reported to be 21 
therapeutically effective. 22 
 23 
Outstanding Questions 24 
How may antibodies, particularly autoantibodies, penetrate inside cells?  25 
Does cell penetration represent a normal function of some antibodies, or is this an aberrant 26 
characteristic of rare autoantibodies only?   27 
What characteristics of either cells or antibody allow for cell penetration? 28 
15 
 
Can cell penetration be optimised to allow for efficient antibody delivery to the cytosol? 1 
Cytosolic Fc receptor TRIM21 has been linked functionally to proteasome dependent 2 
degradation of virus and to autophagy.  3 
Do all cytosolic antibodies engage TRIM21? Are intracellular antigens bound by antibody 4 
degraded by the proteasome or by autophagy? 5 
Do all intracellular antibodies induce innate immune signalling? 6 
The reported therapeutic benefit in tumour metastasis for antibodies targeting intracellular 7 
antigens needs to be confirmed. 8 
 9 
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